Skip to main content
. Author manuscript; available in PMC: 2018 Jun 22.
Published in final edited form as: Shock. 2007 Jun;27(6):623–630. doi: 10.1097/SHK.0b013e31802fa0bd

Fig. 4. Inhibition of the C5a reprogramming effect on LPS-induced IL-6 and TNF-α production by SB203580, a p38 MAPK inhibitor.

Fig. 4

The PBMCs were treated with or without SB203580 for an hour and with or without C5a (100 ng/mL) for an hour, then stimulated with LPS (10 ng/mL) as indicated. White bars represent IL-6 levels; and black bars, TNF-α. Data are represented as mean ± SEM. Results were analyzed using a paired t test.